184 related articles for article (PubMed ID: 19953623)
1. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
Kim S; Eleff M; Nicolaou N
Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
[TBL] [Abstract][Full Text] [Related]
2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
3. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland.
O'Brien CJ; McNeil EB; McMahon JD; Pathak I; Lauer CS; Jackson MA
Head Neck; 2002 May; 24(5):417-22. PubMed ID: 12001070
[TBL] [Abstract][Full Text] [Related]
4. Parotid metastasis--an independent prognostic factor for head and neck cutaneous squamous cell carcinoma.
Ch'ng S; Maitra A; Lea R; Brasch H; Tan ST
J Plast Reconstr Aesthet Surg; 2006; 59(12):1288-93. PubMed ID: 17113505
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
6. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel.
Mecca C; Ponzetti A; Caliendo V; Ciuffreda L; Lista P
Eur J Dermatol; 2012; 22(6):758-61. PubMed ID: 23131415
[TBL] [Abstract][Full Text] [Related]
7. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
8. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice.
Veness MJ; Morgan GJ; Palme CE; Gebski V
Laryngoscope; 2005 May; 115(5):870-5. PubMed ID: 15867656
[TBL] [Abstract][Full Text] [Related]
9. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers.
Forest VI; Clark JJ; Veness MJ; Milross C
Cancer; 2010 Mar; 116(5):1298-304. PubMed ID: 20052712
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
[TBL] [Abstract][Full Text] [Related]
11. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma.
Miller K; Sherman W; Ratner D
Dermatol Surg; 2010 Dec; 36(12):2069-74. PubMed ID: 21044226
[No Abstract] [Full Text] [Related]
12. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
13. Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab.
Rubió Casadevall J; Graña-Suárez B; Hernandez-Yagüe X; Vayreda Ribera J; Huc Grasa O; Brunet Vidal J
Eur J Dermatol; 2009; 19(2):163-5. PubMed ID: 19106040
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
16. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma.
Verduzco-Rodríguez L; Aguirre-González EH; Verduzco-Aguirre HC
Hematol Oncol Stem Cell Ther; 2011; 4(4):182-4. PubMed ID: 22198189
[TBL] [Abstract][Full Text] [Related]
17. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study.
Dattatreya S; Goswami C
Indian J Cancer; 2011; 48(2):154-7. PubMed ID: 21768658
[TBL] [Abstract][Full Text] [Related]
19. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
